/Dexcom%20Inc%20logo%20on%20phone%20-by%20T_Schneider%20via%20Shutterstock.jpg)
San Diego, California-based DexCom, Inc. (DXCM) is a medical technology company focused on continuous glucose monitoring (CGM) systems that enable real-time tracking of blood sugar levels for people with diabetes. Valued at $24.7 billion by market cap, its wearable devices, such as the G6 and next-generation G7, transmit continuous data to smartphones, helping users and healthcare providers manage glucose levels more effectively without frequent fingerstick testing.
The global leader in glucose biosensing is expected to post its fiscal first-quarter earnings for 2026 after the market closes on Thursday, Apr. 30. Ahead of the event, analysts expect DXCM to report a profit of $0.47 per share on a diluted basis, up 46.9% from $0.32 per share in the year-ago quarter. The company beat the consensus estimates in three of the last three quarters while missing the forecast on one occasion.